CLINICAL_TRIALS
trial_result
· 2017-06-01
Clinical Trial Update: Evaluate Safety and Tolerability in Dose Escalation of Sorafenib in Advanced Renal Cell Cancer [Phase 2]
Summary
This Phase 2 trial update reports on the safety and tolerability findings from a dose-escalation study of sorafenib in advanced renal cell carcinoma.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Kansas Medical Center | Conditions: Renal Cell Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-06-01